ARK Genomic Revolution ETF (BATS:ARKG) Shares Sold by Cetera Investment Advisers

Cetera Investment Advisers cut its stake in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 5.5% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 104,179 shares of the company’s stock after selling 6,010 shares during the period. Cetera Investment Advisers owned approximately 0.18% of ARK Genomic Revolution ETF worth $2,453,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hemington Wealth Management raised its position in shares of ARK Genomic Revolution ETF by 44.6% in the 4th quarter. Hemington Wealth Management now owns 1,310 shares of the company’s stock valued at $30,000 after purchasing an additional 404 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new position in shares of ARK Genomic Revolution ETF in the 4th quarter valued at approximately $45,000. BNP Paribas acquired a new position in shares of ARK Genomic Revolution ETF in the 4th quarter valued at approximately $47,000. ARK Investment Management LLC raised its position in shares of ARK Genomic Revolution ETF by 72.7% in the 4th quarter. ARK Investment Management LLC now owns 5,989 shares of the company’s stock valued at $141,000 after purchasing an additional 2,521 shares in the last quarter. Finally, Zuckerman Investment Group LLC acquired a new position in shares of ARK Genomic Revolution ETF in the 4th quarter valued at approximately $188,000.

ARK Genomic Revolution ETF Stock Down 7.6%

Shares of ARKG opened at $21.81 on Monday. The business’s 50 day moving average is $21.48 and its two-hundred day moving average is $23.99. ARK Genomic Revolution ETF has a 52-week low of $17.51 and a 52-week high of $31.16.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.